$AKTX
Akari Therapeutics Plc Stock $aktx

$aktx Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000114420415067423 Filed on November 23, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.360M	$2.730M	$55.45K
YoY Change	7766.67%	4823.78%
% of Gross Profit
Research & Development	$1.930M	$1.313M	$162.6K
YoY Change	78.7%	707.79%
% of Gross Profit
Depreciation & Amortization	$10.00K	-$10.00K	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$4.290M	$23.33M	$218.0K
YoY Change	286.49%	10599.03%
Operating Profit		-$23.33M	-$218.0K
YoY Change		10599.03%
Interest Expense	$10.76M	$3.054M	$2.882K
YoY Change	-107700.0%	105877.17%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$25.41M	-$5.100K
YoY Change		498110.02%
Pretax Income	$6.470M	-$48.74M	-$223.1K
YoY Change	-682.88%	21741.93%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	$6.470M	-$48.74M	-$223.1K
YoY Change	-682.88%	21741.93%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$5.477K	-$62.35K	-$2.999K
COMMON SHARES
Basic Shares Outstanding	1.178B shares	781.7M shares	73.37M shares
Diluted Shares Outstanding		781.7M shares	73.37M shares

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$68.92M	$78.77M
YoY Change
Cash & Equivalents	$68.92M	$78.77M	$52.61K
Short-Term Investments
Other Short-Term Assets	$730.0K	$170.0K
YoY Change
Inventory
Prepaid Expenses
Receivables	$10.00K
Other Receivables	$0.00
Total Short-Term Assets	$69.66M	$78.94M
YoY Change	1988.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$40.51K	$34.93K
YoY Change
Goodwill		$19.28M
YoY Change
Intangibles	$52.48K	$58.10K
YoY Change	-11.67%
Long-Term Investments
YoY Change
Other Assets	$140.0K	$140.0K
YoY Change
Total Long-Term Assets	$235.1K	$235.1K
YoY Change	295.64%
TOTAL ASSETS
Total Short-Term Assets	$69.66M	$78.94M
Total Long-Term Assets	$235.1K	$235.1K
Total Assets	$69.89M	$79.17M
YoY Change	1958.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.321M	$3.754M
YoY Change	677.74%
Accrued Expenses	$408.2K	$3.846M
YoY Change	849.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.12M	$37.80M
YoY Change	1703.44%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$50.00K	$50.00K
YoY Change	51.52%
Total Long-Term Liabilities	$49.07K	$46.04K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.12M	$37.80M
Total Long-Term Liabilities	$49.07K	$46.04K
Total Liabilities	$21.17M	$37.84M
YoY Change	1707.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$56.80M	-$63.27M
YoY Change	394.78%
Common Stock	$105.4M	$104.4M
YoY Change	671.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$48.72M	$41.33M
YoY Change
Total Liabilities & Shareholders Equity	$69.89M	$79.17M
YoY Change	1958.92%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	$6.470M	-$48.74M	-$223.1K
YoY Change	-682.88%	21741.93%
Depreciation, Depletion And Amortization	$10.00K	-$10.00K	$0.00
YoY Change
Cash From Operating Activities	-$6.770M	$5.300M	$3.570M
YoY Change	910.45%	48.46%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$10.00K	$1.410M	$140.0K
YoY Change		907.14%
Cash From Investing Activities	-$20.00K	$1.410M	$140.0K
YoY Change		907.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.060M	72.10M	-7.880M
YoY Change	-178.46%	-1014.97%
NET CHANGE
Cash From Operating Activities	-6.770M	5.300M	3.570M
Cash From Investing Activities	-20.00K	1.410M	140.0K
Cash From Financing Activities	-3.060M	72.10M	-7.880M
Net Change In Cash	-9.850M	78.81M	-4.170M
YoY Change	-404.95%	-1989.93%
FREE CASH FLOW
Cash From Operating Activities	-$6.770M	$5.300M	$3.570M
Capital Expenditures	-$10.00K
Free Cash Flow	-$6.760M
YoY Change	908.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	75445420	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	553654	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52614	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1410577	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63268903	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	2223298	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	79174139	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3394666	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	162575	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1313265	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	55454	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2730434	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-48735690	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-223129	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48735690	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-223129	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	73370267	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	781738789	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	539965	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3869395	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	274195	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3140945	USD
	us-gaap	Net Income Loss NetIncomeLoss	-51789822	USD
	us-gaap	Net Income Loss NetIncomeLoss	-833742	USD
	dei	Document Type DocumentType	10-Q
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-51789822	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-833742	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	72968124	shares
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	742360887	shares
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48778952	USD
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-243520	USD
	dei	Entity Registrant Name EntityRegistrantName	Akari Therapeutics Plc
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51638812	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001541157
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-868121	USD
	us-gaap	Depreciation Depreciation	1455	USD
	us-gaap	Depreciation Depreciation	4424	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	aktx	Increase Decrease In Accounts Receivables And Prepaid Expense IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense	3099	USD
	aktx	Increase Decrease In Accounts Receivables And Prepaid Expense IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense	-1475903	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-808846	USD
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	AKTX
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1804892	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-501040	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	342185	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78772888	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3327468	USD
CY2015Q3	aktx	Accounts Receivable And Prepaid Expenses Net Current AccountsReceivableAndPrepaidExpensesNetCurrent	166141	USD
CY2014Q4	aktx	Accounts Receivable And Prepaid Expenses Net Current AccountsReceivableAndPrepaidExpensesNetCurrent	7781	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	78939029	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	3335249	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34932	USD
CY2015Q3	us-gaap	Assets Assets	79174139	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72104349	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11479081	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	41331446	USD
CY2014Q4	us-gaap	Assets Assets	3394666	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	37796655	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1171368	USD
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	86062364	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2445494	USD
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1177693383	shares
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3753518	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	555528	USD
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1177693383	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1177693383	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	722345600	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	722345600	shares
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	23326979	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	218029	USD
	us-gaap	Operating Expenses OperatingExpenses	26293620	USD
	us-gaap	Operating Expenses OperatingExpenses	814160	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	3054262	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	2882	USD
	us-gaap	Interest Expense InterestExpense	3059898	USD
	us-gaap	Interest Expense InterestExpense	7547	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	76062	USD
CY2015Q3	us-gaap	Deposit Assets DepositAssets	142079	USD
CY2015Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58099	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	59417	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3845928	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	42999	USD
CY2015Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	0	USD
CY2014Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	39236	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-23326979	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-218029	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26293620	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-814160	USD
CY2015Q3	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	3031304	USD
CY2014Q4	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	533605	USD
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	197091	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	46081	USD
CY2015Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1445	USD
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	85	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1445	USD
CY2015Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-22	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	26540	USD
CY2014Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2218	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-60581	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-12120	USD
CY2015Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-43262	USD
CY2014Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-20391	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	151010	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-34379	USD
CY2015Q3	us-gaap	Taxes Other TaxesOther	21425	USD
CY2014Q3	us-gaap	Taxes Other TaxesOther	0	USD
	us-gaap	Taxes Other TaxesOther	42721	USD
	us-gaap	Taxes Other TaxesOther	0	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-25408711	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5100	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-25496202	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19582	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	750000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6638855	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	439	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	53594714	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	24896	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1410577	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	3031304	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	508713	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	75000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	237090	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5418242	USD
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	112300	USD
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	0	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	125602	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-34379	USD
	us-gaap	Interest Paid InterestPaid	22662	USD
	us-gaap	Interest Paid InterestPaid	12	USD
CY2015Q3	aktx	Percentage Of Total Shares Issued PercentageOfTotalSharesIssued	0.9285	pure
CY2015Q3	aktx	Percentage Of Total Shares Issued On Diluted Basis PercentageOfTotalSharesIssuedOnDilutedBasis	0.9168	pure
	aktx	American Depositary Shares Description AmericanDepositarySharesDescription	each representing 100
	aktx	Business Combination Share Exchange BusinessCombinationShareExchange	721:1
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.55pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.55pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Use of Estimates -</font></strong> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities. Management’s estimates and judgments include assumptions used in the impairment and useful lives of intangible assets, accrued liabilities, deferred income taxes, liabilities related to stock options and warrants, stock-based compensation and various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.55pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.55pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> Concentration of Credit Risk -</font></strong> <font style="FONT-SIZE: 10pt">Financial instruments that subject the Company to credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents with well-capitalized financial institutions. At times, those amounts may exceed insured limits. The Company has no significant concentrations of credit risk.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	151010	USD
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	44000	USD
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	25000	USD
CY2015Q3	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	20339140	USD
CY2015Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	1410577	USD
CY2015Q3	aktx	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumedrestricted Deposit BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedrestrictedDeposit	142079	USD
CY2015Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	1672028	USD
CY2015Q3	us-gaap	Goodwill Goodwill	19283280	USD
CY2015Q3	aktx	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumedstock Options And Warrants BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedstockOptionsAndWarrants	1800581	USD
CY2015Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	368243	USD
CY2015Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	20339140	USD
CY2015Q3	us-gaap	Business Acquisition Percentage Of Voting Interests Acquired BusinessAcquisitionPercentageOfVotingInterestsAcquired	0.9168	pure
CY2014Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	0	USD
	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	638691	USD
	aktx	Increasedecreasein Values Of Liability Related To Stock Options IncreasedecreaseinValuesOfLiabilityRelatedToStockOptions	26004442	USD
CY2015Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	27165905	USD
	aktx	Fair Value Of Liability Related To Stock Options And Warrants Acquisition FairValueOfLiabilityRelatedToStockOptionsAndWarrantsAcquisition	1800154	USD
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	781738789	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73370267	shares
CY2015Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2014Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	781738789	shares
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73370267	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	742360887	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72968124	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	742360887	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72968124	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	63845378	shares
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	63845378	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	27000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	0	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	5617977	shares
CY2015Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.18945
CY2015Q3	aktx	Warrant Issunance Exercise Price Description WarrantIssunanceExercisePriceDescription	share or warrant issuance at less than $0.1958 price share or exercise price per share
CY2015Q3	aktx	Liability Related To Stock Options And Warrants LiabilityRelatedToStockOptionsAndWarrants	27165905	USD
CY2014Q4	aktx	Liability Related To Stock Options And Warrants LiabilityRelatedToStockOptionsAndWarrants	0	USD
CY2014Q4	us-gaap	Deposit Assets DepositAssets	0	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	18340894	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	11210804	USD
CY2015Q3	us-gaap	Other Financial Services Costs OtherFinancialServicesCosts	22973138	USD
CY2014Q3	us-gaap	Other Financial Services Costs OtherFinancialServicesCosts	0	USD
	us-gaap	Other Financial Services Costs OtherFinancialServicesCosts	22973138	USD
	us-gaap	Other Financial Services Costs OtherFinancialServicesCosts	0	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.00
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2015Q3	aktx	Share Based Compensation Arrangement By Share Based Payment Award Options And Warrants Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsOutstandingNumber	631970	shares
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	76062	USD
CY2014Q4	us-gaap	Liabilities Liabilities	1171368	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	76000	USD
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11400000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	7205	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2015Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	3000000	USD
CY2015Q3	aktx	Stock Options And Warrants Fair Value Disclosure StockOptionsAndWarrantsFairValueDisclosure	26004442	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	26000000	USD
CY2015Q3	us-gaap	Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued	188303	shares
	us-gaap	Interest Expense Other InterestExpenseOther	3000000	USD
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	2481690	shares
CY2015Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1782246	shares
CY2015Q3	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	19283280	USD
CY2014Q3	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	0	USD
	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	19283280	USD
	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	0	USD
CY2015Q3	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	638691	USD
CY2014Q3	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	USD
	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	69581758	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	750000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	20339140	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3031304	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-638691	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	3000000	USD
	us-gaap	Financing Interest Expense FinancingInterestExpense	22973138	USD
CY2015Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	46038	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2015Q3	us-gaap	Liabilities Liabilities	37842693	USD
	us-gaap	Financing Interest Expense FinancingInterestExpense	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center"></div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; WIDTH: 100%; PADDING-RIGHT: 0px; BORDER-TOP: black 1pt solid; PADDING-TOP: 0px"> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>NOTE 1 - Nature of Business</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Akari Pharmaceuticals, Plc, (the “Company” or “Akari”), formerly Celsus Therapeutics Plc (“Celsus”), is incorporated <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">in the United Kingdom</font>. The Company is a clinical stage biotechnology company, and is focused on developing anti-complement and anti-inflammatory molecules as treatments for a wide range of rare and orphan conditions in the autoimmune and inflammatory diseases sectors.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 3.65pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On September 18, 2015, Celsus Therapeutics Plc completed its acquisition of all of the capital stock of Volution Immuno Pharmaceuticals SA (“Volution”), from RPC Pharma Limited (“RPC”), Volution’s sole shareholder, in exchange for ordinary shares, par value £<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font>, (“Ordinary Shares”), of Celsus (the “Acquisition”), in accordance with the terms of the Share Exchange Agreement, dated as of July 10, 2015 (the “Agreement”), by and among the Celsus and RPC.  In connection with the Acquisition, the name of the combined company was changed to Akari Therapeutics, Plc. The Company’s American Depositary Shares (“ADSs”), <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> each representing 100</font> Ordinary Shares, began trading on The NASDAQ Capital Market under the symbol “AKTX” on September 21, 2015. </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In connection with the consummation of the Acquisition, Celsus issued an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 722,345,600</font> Ordinary Shares to RPC, which represented, prior to giving effect to the Financing (defined below), <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 92.85</font>% of Celsus’s outstanding Ordinary Shares following the closing of the Acquisition (or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 91.68</font>% of Celsus Ordinary Shares on a fully diluted basis). This yielded a share exchange ratio of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 721:1</font> of Akari ordinary shares to RPC shares. The Company's earnings per share have been retrospectively adjusted in the statement of operations to reflect this recapitalization. Since the Volution securityholders owned a majority of the capitalization of the Company immediately following the closing of the Acquisition, Volution is considered to be the acquiring company for accounting purposes, and the transaction has been accounted for as a reverse acquisition under the acquisition method of accounting for business combinations in accordance with U.S. GAAP. Accordingly, the assets and liabilities of Celsus have been recorded as of the acquisition closing date at fair value.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company, as used in the accompanying notes to the combined and condensed financial statements, refers to Volution prior to the Acquisition and Akari subsequent to the completion of the Acquisition.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In addition, on September 18, 2015, the Company completed a private placement of an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,958,811</font> restricted ADSs representing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 395,881,100</font> Ordinary Shares for gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75</font> million (the “Financing”) at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18.945</font> per restricted ADS, which represented approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 33.3</font>% of the outstanding Ordinary Shares of the Company after giving effect to the Acquisition and the Financing.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Volution was originally incorporated in Switzerland as a private limited company and commenced business on October 9, 2013. On October 23, 2013, Varleigh Immuno Pharmaceuticals Ltd (“Varleigh”), a UK limited company, transferred certain patent rights to Volution in exchange for a payment of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">107,000</font>, (GBP <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 65,000</font>), which was the carrying value of the patents in accordance with local accounting standards. Effective September 12, 2014 Varleigh ceased its operations and was dissolved. The transaction resulted in the transfer of the business of Varleigh to Volution. On the date of transfer, the controlling/majority shareholders of Volution were also the controlling/majority shareholders of Varleigh. Upon dissolution, there were no reported assets, liabilities, or accumulated comprehensive income remaining in Varleigh, as such no gain or loss on dissolution was recognized.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">   </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On July 3, 2015, the shareholders of Volution exchanged their shares for RPC shares with no changes in individual share ownerships. This qualified as a reorganization.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt">The Company is subject to a number of risks similar to those of clinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations is dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of revenues adequate to support the Company’s cost structure. There are no assurances that the Company will be able to obtain additional financing on favorable terms, or at all or successfully market its products.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1150276	shares
CY2015Q3	aktx	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	1.96

Files In Submission

Name	View Source	Status
0001144204-15-067423-index-headers.html	Edgar Link	pending
0001144204-15-067423-index.html	Edgar Link	pending
0001144204-15-067423.txt	Edgar Link	pending
0001144204-15-067423-xbrl.zip	Edgar Link	pending
aktx-20150930.xml	Edgar Link	completed
aktx-20150930.xsd	Edgar Link	pending
aktx-20150930_cal.xml	Edgar Link	unprocessable
aktx-20150930_def.xml	Edgar Link	unprocessable
aktx-20150930_lab.xml	Edgar Link	unprocessable
aktx-20150930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v424419_10q.htm	Edgar Link	pending
v424419_ex31-1.htm	Edgar Link	pending
v424419_ex31-2.htm	Edgar Link	pending
v424419_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AKTX
Akari Therapeutics Plc Stock $aktx

2015 Q4 Form 10-Q Financial Statement

#000114420415067423 Filed on November 23, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKTX Akari Therapeutics Plc Stock $aktx

2015 Q4 Form 10-Q Financial Statement

#000114420415067423 Filed on November 23, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKTX
Akari Therapeutics Plc Stock $aktx